reason report
bottom line reiter op rate ci post strong
 rais qualiti beat driven healthcar
off-set miss global supplement claim experi
rais ep line midpoint
guidanc manag commentari suggest stand-alone
ci unlik upsid consensu given challeng comp
prior-year develop headwind margin compress
individu book given competit intens maintain ep
esrx mp close look immin doj approv
state estim ep accret ex-antm op
consist manag commentari competit confer
septemb post esrx ep manag
reiter ep take account potenti
elimin mm rebat ad bullish
strateg valu deal expect go-to-market strategi
esrx combin guid administr cost effici coupl
increment medic synergi guidanc drive
revenu growth normal basi merg entiti
cross sell bundl product across rx medic middl
market select market ci alreadi domin player
cash flow post esrx fuel debt pay high
debt-to-capit ratio within month fuel share repurchas
smaller deal medicar advantag renew focu
expect growth margin expans name trade
meaning discount peer stand-alon basi
esrx ep see deal close guidanc
upsid earn catalyst unlock valu maintain pt
strong rais rais ep line
guidanc midpoint rais above-consensu
revenu ep global healthcar out-performance
commerci govern offset pressur claim
experi global supplement commerci membership grew
sequenti steadi govern membership global supplement
saw unfavor claim experi margin compress qoq
yoy metric day claim payabl cfo ni
exhibit
maintain stand-alon ep given
commentari mm headwind individu margin
compress challeng comp prior-year favor
stand-alon ep
net debt total capit
price-to-earnings lt ep growth
estimate lt ep growth compound-annual-growth-rate
compani inform leerink partner llc research
revenu billion quarterli number may add total due round
ep exclud item non-gaap ep quarterli number may add total due round
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
esrx offer solid ep accret toward
even adjust loss contract esrx retain
health plan busi though price aggress
expect go-to-market strategi esrx
combin guid administr cost effici coupl
increment medic synergi guidanc drive
revenu growth normal basi post esrx deal
cross sell bundl product across rx medic
middl market select market ci alreadi domin
player aso plu stop loss offer exhibit
manag reiter ep take
account potenti elimin mm rebat
manag perspect view esrx ad scale best
class capabl ci industri move integr model
manag umbrella align busi model
employ govern custom exhibit
annual cash flow post esrx fuel debt pay
high debt-to-capit ratio within month fuel
share repurchas smaller deal exhibit
manag confid medicar
advantag growth aspect target high-single-digit growth
revenu improv rate also set ci new
name trade meaning discount peer
stand-alon basi esrx ep see
deal close guidanc upsid earn catalyst unlock
reiter op rate ci post strong rais qualiti beat driven
healthcar off-set miss global supplement claim experi
rais ep line midpoint guidanc manag
commentari suggest stand-alone ci unlik upsid consensu given
challeng comp prior-year develop headwind margin compress
individu book given competit intens maintain ep esrx close
look immin doj approv state estim ep accret
ex-antm consist manag commentari competit confer septemb
post esrx ep manag reiter ep
take account potenti elimin mm rebat ad bullish
strateg valu deal expect go-to-market strategi esrx
combin guid administr cost effici coupl increment medic synergi
guidanc drive revenu growth normal basi merg
entiti cross sell bundl product across rx medic middl market
select market ci alreadi domin player aso plu stop loss offer
annual cash flow post esrx fuel debt pay high within
month fuel share repurchas smaller deal medicar advantag renew
focu expect growth margin expans name trade meaning
discount peer stand-alon basi esrx ep
see deal close guidanc upsid earn catalyst unlock valu
strong rais rais ep line guidanc
midpoint rais above-consensu revenu ep global
healthcar out-performance commerci govern offset pressur
claim experi global supplement commerci membership grew sequenti
steadi govern membership global supplement saw unfavor claim experi
margin compress qoq yoy metric day claim payabl cfo
ni
strong revenu also better expect
ci earningsreport estimatesstreetaccount consensusreport sequentialreport yoytot net incom loss operationsglob disabl supplement incom loss oper per shareglob disabl supplement order invest corpor
consolid bp partial off-set global supplement claim experi
dcp remain stabl day sequenti
claim payabl corpor
ci rais guidanc revenu growth ep midpoint
maintain stand-alon ep given commentari mm
headwind individu margin compress challeng comp prior-year
favor develop rais ep estim line midpoint
guidanc
ci guidanceguid estimatesconsensu estimatesconsolid revenueyoy revenu medic membership growth medic medic health total oper expens health earn disabl life earn supplement benefit adj net incom guidanc exclud share corpor
maintain ep estim
individu margin compress headwind mn
esrx offer solid ep accret toward even adjust
loss contract esrx retain health plan busi though price
aggress pbm sell season
esrx close look immin doj approv state
incom non bp deliv particularli strong perform year individu busi margin excess target level expect achiev margin line long-term expect busi repres approxim million after-tax earn headwind step michael cordani presid ceo director corp call corpor
transact still subject state regulatori approv achiev far
satisfact close condit
expect go-to-market strategi esrx combin guid
administr cost effici coupl increment medic synergi
guidanc drive revenu growth normal basi post esrx deal cross
sell bundl product across rx medic middl market select
market ci alreadi domin player aso plu stop loss offer
cross sell bundl product across rx medic middl market select market
like provid specif regulatori integr plan updat regard pend combin express script septemb secur perman financ combin depart justic clear transact state level continu make good progress achiev approv six approv remain continu expect close transact end year david michael cordani presid ceo director corp calla relat aso consist trend year relat marketplac embrac transpar demand transpar varieti lens aso mechan know prior convers one reason passion aso transpar present opportun align align present opportun speed share execut necessari trend consist amplifi yet integr differ bundl cross-sel truli integr around whole person inform flow incent benefit design clinician see continu grow well posit david michael cordani presid ceo director corp call corpor
cross-sel offer addit growth opportun ci esrx combin
manag reiter ep
manag reiter ep take account potenti
elimin mm rebat view esrx ad scale best class
capabl ci industri move integr model manag umbrella
align busi model employ govern custom
ci link file show esrx mp retain mm rebat spend per year
suggest elimin rebat would manag mid-single-digit
ebitda exposur pleas see link note link
revenu growth rollforwardstatu quo pro forma growth growth relat core plaform includ medicar advantag part growth relat express script enchanc reach expans term revenu increment growth opportun ci-esrx combin express script employ custom overlap approxim substanti cross-sel opportun product servic area express script also servic health plan govern entiti health servic capabl program expand area current oper well-perform senior busi highli reliant pharmaci servic express script lead capabl drive lower drug cost popul oper competit target go deeper geographi leverag express script stand-alon servic capabl abl quickli expand compet outsid go deeper geographi greenfield opportun exist key geographi neither express script signific health plan relationshipsbi leverag express script pharmaci manag servic abl deepli drive value-bas model healthcar provid pharmaceut manufactur therebi creat addit valu custom corpor
manag reiter ep
guid accret driven entir mm administr synergi
also expect achiev step function growth revenu earn combin express script combin compani expect continu drive strong margin free cash flow enabl us rapidli reduc debt level continu reinvest capabl addit capit avail deploy well posit attract revenu ep growth standpoint remain track deliv ep commit per share david michael cordani presid ceo director corp call corpor
annual cash flow post esrx fuel debt pay high debt-to-capit
ratio within month fuel share repurchas smaller deal
ci strong capit posit parent ci-esrx combin expect
gener
manag confid medicar advantag growth aspect
target high-single-digit growth revenu improv rate also set
ci new market entri
manag posit growth rate
regard free cash flow end first quarter parent compani cash billion consid sourc use parent compani cash continu expect capit avail deploy billion forward project combin compani gener free cash flow least billion eric palmer cfo execut vice presid corp callspecif excit outlook would remind strateg goal grow book busi high singl digit revenu rang also remind compet deliv signific valu individu marketplac group marketplac excit growth opportun look forward note prior question realli well-posit well step current point strength corpor rate new market entri attract posit team excit david michael cordani presid ceo director corp call corpor
name trade meaning discount peer stand-alon basi
esrx ep see deal close guidanc upsid
earn catalyst unlock valu
ci trade price-to-earnings consensu ep
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform dcf valuat
leverag forward forecast wacc termin growth rate inform
potenti multipl expans along sector compani specif catalyst expect
greater potenti multipl expans dcf valuat point significantli upsid
peer current trade level
free cash flow yield ratio also inform potenti multipl expans
except low ratio and/or high free cash flow yield point potenti greater
multipl expans use absolut rel price-to-earnings multipl base approach valuat
ep estim combin price-to-earnings base approach dcf model point
intrins valu compani plu add premium deal probabl
price target repres price-to-earnings ep
downsid risk invest thesi valuat aet legisl regulatori
polici chang could either dis-intermedi health insur us benefit
marketplac place unforeseen top-lin margin headwind commerci medicar
advantag medicaid dual elig book busi not-for-profit health insur
price irrat commerci health benefit marketplac acceler employ exit
sponsorship health benefit us marketplac post implement
afford act advers select public exchang protect adequ
given delay true-up govern payment acquisit asset
without attract return capit investor organiz and/or oper risk
lead execut mis-step downsid risk earn
upsid risk invest thesi valuat aet accret acquisit
aggress share repurchas use solid parent cash posit debt rais
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level free cash flow yield ratio also inform
potenti multipl expans except low ratio and/or high free cash flow yield
point potenti greater multipl expans
pt contempl price-to-earnings ep
risk invest thesi valuat
legisl regulatori polici chang could either dis-intermedi
insur us benefit marketplac place unforeseen top-lin margin
headwind commerci medicar advantag medicaid dual elig book
not-for-profit health insur price irrat commerci health benefit
acceler employ exit sponsorship health benefit us
marketplac post implement afford act
advers select public exchang protect adequ given delay
true-up govern payment
acquisit asset without attract return capit investor
organiz and/or oper risk drive execut mis-step downsid risk
earn
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform dcf valuat
leverag forward forecast wacc termin growth rate inform
potenti multipl expans along sector compani specif catalyst expect
greater potenti multipl expans dcf valuat point significantli upsid
peer current trade level free cash flow yield ratio also inform
potenti multipl expans except low ratio and/or high free cash flow yield
point potenti greater multipl expans
base price-to-earnings multipl appli stand-alon ep rate ci
outperform price target
non-profit bcb plan insur price irrat commerci market rapidli
medic cost trend come higher anticip potenti econom downturn
provid re-up intens servic deliveri cobra acceler uptak
member util care advanc layoff pandem
employ exit rapidli sponsorship health benefit combat medic cost
inflat catalyz econom downturn
risk declin invest yield invest impair
state-bas actuari rate review limit sound price underwrit caus
longer term state-bas insur exchang advers select reduc
sustain earn power employ dump employe health insur
exchang signific margin compress potenti downsid membership
polit shock lead singl payer
compani specif risk signific declin equiti market could result increas fund
compani pension oblig polit legal oper regulatori econom
risk foreign oper
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level free cash flow yield ratio also inform
potenti multipl expans except low ratio and/or high free cash flow yield
point potenti greater multipl expans price target base case
ep estim
risk valuat includ
start-up cost underwrit issu associ new busi on-board
particularli challeng new popul dual elig
annual off-cycl rate chang state medicaid program
uncertainti associ competit bid process state
legisl regulatori judici polici chang medicaid entitl program
state feder suprem court level also risk consid
remain posit reiter op rate month pt
contempl price-to-earnings ep
risk invest thesi valuat legisl regulatori
polici chang could either dis-intermedi health insur us benefit
marketplac place unforeseen top-lin margin headwind commerci medicar
advantag medicaid dual elig book busi not-for-profit health insur
price irrat commerci health benefit marketplac acceler employ exit
sponsorship health benefit us marketplac post implement
afford act advers select public exchang protect adequ
given delay true-up govern payment acquisit asset
without attract return capit investor organiz and/or oper risk
lead execut mis-step downsid risk earn acceler medic cost
trend util improv economi
pt reflect price-to-earnings ep
start-up cost underwrit issu associ new busi on-board
particularli challeng new popul dual elig
annual off-cycl rate chang state medicaid program
uncertainti associ competit bid process state
legisl regulatori judici polici chang medicaid
scale issu result loss specialti rx pharmaci contract
acquisit offer adequ return capit
upsid takeout substanti premium key risk
carve-out behavior health servic current state contract
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level
free cash flow yield ratio also inform potenti multipl expans
except low ratio and/or high free cash flow yield point potenti greater
base post month turnaround rate outperform pt
contempl price-to-earnings ep
risk highlight first spike util on-board new state contract
dual elig integr second state-bas insur exchang result advers
select reduc sustain earn power third state-bas contract rate increas
suffici cover medic trend off-set industri fee medicaid premium fourth risk re-
procur exist contract could creat substanti downsid risk volatil fifth
legisl judici risk manag medicaid entitl extrem case singl
payer model also possibl downsid
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level
free cash flow yield ratio also inform potenti multipl expans
except low ratio and/or high free cash flow yield point potenti greater
rate outperform price target contempl price-to-earnings
cash ep
non-profit bcb plan insur price irrat commerci market rapidli
medic cost trend come higher anticip potenti double-dip recess
provid re-up intens servic deliveri cobra acceler uptak member util
care advanc lay-off pandem
employ exit rapidli sponsorship health benefit combat medic cost
inflat catalyz double-dip recess
risk declin invest yield invest impair
state-bas actuari rate review limit sound price underwrit caus substanti
long-term state base health insur exchang advers select reduc
sustain earn power employ dump employe health insur
exchang signific margin compress also potenti downsid membership
risk relat collect industri fee medicar medicaid premium
polit shock lead singl payer
compani specif risk downsid risk price target includ acquisit asset
arena yield adequ return capit
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level
free yield ratio also inform potenti multipl expans
except low ratio and/or high free yield point potenti greater
base rate wcg outperform pt contempl price-to-earnings
ep
downsid risk price target includ execut new state contract dual elig
award rate increas suffici cover medic trend state clawback tax off-set tax
reform tailwind potenti dial medicaid expans ky upsid risk price
target includ take-out larger player
cigna inc ci incom mail order pharmaci invest invest gain expenseshealth care medic claim benefit order pharmaci cost good acquisit oper expens exclud special benefit continu oper incom tax net growth cigna corpor
health enrol access/oth guarante guarante legaci servic great west medic membership medic membership gw corpor
